Martin Mackay is Director of CHARLES RIVER LABORATORIES INTERNATIONAL, INC.. Currently has a direct ownership of 12,531 shares of CRL, which is worth approximately $2.35 Million. The most recent transaction as insider was on May 13, 2024, when has been sold 931 shares (Common Stock) at a price of $228.41 per share, resulting in proceeds of $212,649. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 12.5K
0% 3M change
8.03% 12M change
Total Value Held $2.35 Million

MARTIN MACKAY Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 13 2024
BUY
Grant, award, or other acquisition
$212,649 $228.41 p/Share
931 Added 6.92%
12,531 Common Stock
Jul 03 2023
BUY
Grant, award, or other acquisition
-
95 Added 0.81%
11,600 Common Stock
May 31 2023
BUY
Grant, award, or other acquisition
-
338 Added 2.85%
11,505 Common Stock
May 15 2023
BUY
Grant, award, or other acquisition
-
664 Added 5.61%
11,167 Common Stock
May 11 2022
BUY
Grant, award, or other acquisition
-
841 Added 7.41%
10,503 Common Stock
Jan 03 2022
BUY
Grant, award, or other acquisition
-
63 Added 0.65%
9,662 Common Stock
May 07 2021
BUY
Grant, award, or other acquisition
-
574 Added 5.64%
9,599 Common Stock

Also insider at

FVAM
5:01 Acquisition Corp. Financial Services
RLYB
Rallybio Corp Healthcare
SWTX
SpringWorks Therapeutics, Inc. Healthcare
MM

Martin Mackay

Director
Wilmington, MA

Track Institutional and Insider Activities on CRL

Follow CHARLES RIVER LABORATORIES INTERNATIONAL, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRL shares.

Notify only if

Insider Trading

Get notified when an Charles River Laboratories International, Inc. insider buys or sells CRL shares.

Notify only if

News

Receive news related to CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Track Activities on CRL